| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 931 | 7.352 | 11.984 | 10.174 | 67.867 | 82.262 |
| Total Income - EUR | - | - | - | - | 931 | 7.352 | 11.984 | 10.187 | 67.867 | 82.263 |
| Total Expenses - EUR | - | - | - | - | 867 | 1.720 | 848 | 2.073 | 26.153 | 41.988 |
| Gross Profit/Loss - EUR | - | - | - | - | 65 | 5.632 | 11.136 | 8.114 | 41.714 | 40.275 |
| Net Profit/Loss - EUR | - | - | - | - | 37 | 5.474 | 10.960 | 7.871 | 41.070 | 38.177 |
| Employees | - | - | - | - | 0 | 0 | 0 | 1 | 2 | 2 |
Check the financial reports for the company - Angiofluxmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 673 | 473 | 396 | 7.859 | 24.332 | 30.695 |
| Current Assets | - | - | - | - | 1.085 | 5.079 | 11.843 | 12.408 | 23.443 | 19.320 |
| Inventories | - | - | - | - | 307 | 0 | 0 | 331 | 0 | 982 |
| Receivables | - | - | - | - | 0 | 253 | 437 | 836 | 3.750 | 0 |
| Cash | - | - | - | - | 778 | 4.826 | 11.406 | 11.241 | 19.694 | 18.338 |
| Shareholders Funds | - | - | - | - | 79 | 5.552 | 12.143 | 20.052 | 43.877 | 46.247 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 1.678 | 0 | 96 | 215 | 3.911 | 3.877 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Angiofluxmed S.r.l.